Expert Committee on Drug Dependence Information Repository

Substance Records

( (8) | 1 (12) | 2 (16) | 3 (19) | 4 (22) | 5 (10) | 6 (2) | 7 (2) | A (40) | B (31) | C (32) | D (51) | E (22) | F (16) | G (4) | H (12) | I (2) | J (3) | K (5) | L (12) | M (53) | N (35) | O (9) | P (51) | Q (1) | R (5) | S (5) | T (24) | U (2) | V (3) | X (1) | Z (4)
Title Drug Class Year(s) and type of review / ECDD meetings
5,6-methylenedioxy-2-aminoindane stimulant

Added to surveillance list by 2nd WG meeting (2017)
5-APB 5-(2-aminopropyl)benzofuran stimulant

Added to surveillance list by 2nd WG meeting (2017)
5-MAPB stimulant

Added to surveillance list by 2nd WG meeting (2017)
5-Methoxy-3,4-methylenedioxyamphetamine stimulant 22nd ECDD (1985) - Critical review
5-Methoxy-N,N-diallyltryptamine hallucinogen 43rd ECDD (2020) - Critical review
5F-ADB/5F-MDMB-PINACA cannabinoid 39th ECDD (2017) - Critical review
5F-AMB-PINACA cannabinoid 42nd ECDD (2019) - Critical review
5F-APINACA (5F-AKB-48) cannabinoid 38th ECDD (2016)- Critical Review
5F-MDMB-PICA cannabinoid 42nd ECDD (2019) - Critical review
5F-PB-22 cannabinoid 39th ECDD (2017) - Critical review